Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Trading Statement

3 Nov 2015 07:00

RNS Number : 2905E
Biome Technologies PLC
03 November 2015
Ā 

03 November 2015

Ā 

Ā 

Biome Technologies plc

("Biome", the "Company" or the "Group")

Ā 

Trading Update

Ā 

Ā 

Biome Technologies plc, a leading bioplastics and radio frequency technology business, today publishes its trading update for the nine-month period ended 30 September 2015.Ā 

Total Group revenues achieved in Q3 were £1.3m, 169% ahead of the same quarter last year (2014: £0.5m). This takes Group revenues for the nine months to 30 September 2015 to £3.3m, 18% ahead of the prior year period (2014: £2.8m).

The Group made a small profit before interest, tax, depreciation, amortisation, and share option charges in the third quarter (based on unaudited management accounts).

Ā 

This performance meets one of the Group's long-term strategic KPIs, established in March 2014, of passing the 'earnings positive' inflexion point in quarterly trading during 2015.

The Group's cash position as at 30 September 2015 was £1.7m (30 June 2015: £1.8m).

Bioplastics Division

Ā 

Revenues in the Bioplastics division in Q3 were £0.5m (Q3 2014: £0.1m) reflecting, amongst other factors, stability in the US single-serve coffee market compared to the downturn seen in the second half of 2014.

Ā 

A new product line comprising temperature-tolerant materials suitable for injection moulding has reached commercialisation and first shipments were made during the quarter. Management expect that revenues from these products will build in the coming months.

Ā 

To complement the division's existing product range, a further product is being developed for a non-woven biodegradable mesh suitable for liquid filtration. This product is in the process of being tested by several end customers with encouraging initial results.

Ā 

Forward order visibility for the division is encouraging for the remainder of the year.

Ā 

Stanelco RF Technologies Division

Ā 

Revenues for Q3 in the RF Technologies division were £0.8m (Q3 2014: £0.4m). This year's orders and shipments are weighted towards the second half and this revenue growth includes elements of the recently announced £1.1m contract to supply multiple furnaces, as well as progress on the contract announced last year to supply advanced analytical equipment to a UK regulated-industry sector.

Ā 

Order levels within the division remain high with a substantial pipeline stretching beyond the remainder of the year and into 2016.

Ā 

Outlook

Ā 

Revenues and order flow in both divisions remain encouraging and the Board is now confident that Group revenues for the year ending 31 December 2015 will show a meaningful improvement against current market expectations, with a resultant reduced operating loss compared to these expectations.

Ā 

Paul Mines, Chief Executive, said:

Ā 

"Revenue generation is strong in both divisions and, coupling this with the achievement of a small group EBITDA profit in the quarter, we are increasingly confident that 2015 will become a very significant milestone in Biome's development."

Ā 

Ā 

- Ends -

Ā 

Ā 

Ā 

For further information please contact:

Ā 

Biome Technologies plc

Ā 

Paul Mines, Chief Executive Officer

Ā 

www.biometechnologiesplc.com

Tel: +44 (0) 2380 867 100

Ā 

Ā 

Ā 

Allenby Capital

Ā 

David Hart/Alex Brearley (Nominated Adviser)

Chris Crawford/Kelly Gardiner (Broker)

Ā 

www.allenbycapital.com

Tel: +44 (0) 20 3328 5656

Ā 

Ā 

Ā 

FTI Consulting

Ā 

Oliver Winters

www.fticonsulting.com

Tel: +44 (0) 20 3727 1535

Ā 

Ā 

Ā 

This information is provided by RNS
The company news service from the London Stock Exchange
Ā 
END
Ā 
Ā 
TSTDLLFBEFFLFBK
Date   Source Headline
15th May 20067:01 amRNSAppointment of Adviser
3rd May 20061:05 pmRNSNotifiable Interest
2nd May 20064:58 pmRNSResult of AGM
2nd May 20062:00 pmRNSAGM Statement
10th Apr 20063:12 pmRNSAnnual Report and Accounts
7th Apr 20062:46 pmRNSAdditional Listing
13th Mar 20067:02 amRNSDirectorate Change
28th Feb 20067:02 amRNSPreliminary Results
24th Feb 20067:02 amRNSCooperation with Wal-Mart
14th Feb 20069:07 amRNSAdditional Listing
14th Feb 20067:00 amRNSUS FDA approval for Starpol
9th Feb 200610:42 amRNSIsraCaps new licence terms
9th Feb 20067:02 amRNSRe: BioProgress plc
16th Dec 20057:01 amRNSFunding for R&D facility
16th Dec 20057:01 amRNSPre Close Update
14th Dec 20057:01 amRNSLandmark deal with Perseco
8th Dec 200510:25 amRNSShare Listing Application
30th Nov 20055:40 pmRNSDirectorate Change
28th Nov 20059:24 amRNSBoard Changes
8th Nov 20057:01 amRNSPatent sale process update
3rd Nov 20054:47 pmRNSExercise of Options
1st Nov 20057:02 amRNSChange of Adviser
12th Oct 20057:00 amRNSApproval of Starpol
3rd Oct 20057:00 amRNSPatent Disposal & Update
22nd Sep 20057:02 amRNSRe Agreement
12th Sep 20057:03 amRNSDevelopment of capsule
5th Sep 20057:03 amRNSRe: Completion
30th Aug 20053:30 pmRNSDoc re. Result of EGM
30th Aug 200511:08 amRNSEGM Statement
30th Aug 20057:03 amRNSRe Agreement
5th Aug 200511:15 amRNSRe posting of circular
1st Aug 20057:01 amRNSDirector Appointment
28th Jul 20057:01 amRNSUpdate re: trials with ASDA
26th Jul 20057:00 amRNSContract Win
19th Jul 20057:00 amRNSRe Agreement
5th Jul 20057:01 amRNSRe Joint Venture
29th Jun 20057:00 amRNSInterim Results
22nd Jun 20057:00 amRNSUpdate re trials with Asda
8th Jun 20055:29 pmRNSAdditional Listing
8th Jun 200510:00 amRNSAppointment of Group MD
8th Jun 20057:50 amRNSPlacing of Ordinary Shares
6th Jun 20057:01 amRNSAcquisition
3rd Jun 20053:02 pmRNSIssue of Equity
23rd May 20057:01 amRNSRe Contract
17th May 200512:12 pmRNSAdditional Listing
10th May 20057:00 amRNSUpdate re. trials with Asda
29th Apr 20053:46 pmRNSHolding(s) in Company
25th Apr 20053:27 pmRNSDirector Shareholding
22nd Apr 20052:24 pmRNSResult of AGM
22nd Apr 200511:31 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.